Prestige closes LaCorium acquisition for ~$150M, prices $400M notes at 6.25% due 2034

Prestige Consumer Healthcare Inc.

Completed acquisition of LaCorium Health for ~$150M cash; LaCorium has ~$40M annual revenue, expected ~$12M EBITDA post-synergies.
Priced $400M senior notes at 6.25% due 2034; proceeds to redeem existing 5.125% notes due 2028.
Borrowed $95M additional term loans under existing credit agreement to finance part of acquisition.
Q1 FY2027 earnings results to be released on August 6, 2026, with conference call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.